Melanoma Associated Antigen 100+ / 7 kDa Antibody [G24P23]

Catalog No.: F3175

Application: Reactivity: Human

Immunohistochemical analysis of formalin fixed paraffin embedded human melanoma tissue with F3175 at 1:20 dilution.

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
IHC1:5 - 1:20

Application
IHC, FCM

Source
Mouse Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

ポジティブコントロール	Human melanoma; Malme-3
ネガティブコントロール

プロトコール

IHC
Experimental Protocol： Deparaffinization/Rehydration 1. Deparaffinize/hydrate sections: 2. Incubate sections in three washes of xylene for 5 min each. 3. Incubate sections in two washes of 100% ethanol for 10 min each. 4. Incubate sections in two washes of 95% ethanol for 10 min each. 5. Wash sections two times in dH2O for 5 min each. 6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min. Staining 1. Wash sections in dH2O three times for 5 min each. 2. Incubate sections in 3% hydrogen peroxide for 10 min. 3. Wash sections in dH2O two times for 5 min each. 4. Wash sections in wash buffer for 5 min. 5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature. 6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C. 7. Remove antibody solution and wash sections with wash buffer three times for 5 min each. 8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature. 9. Wash sections three times with wash buffer for 5 min each. 10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use. 11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity. 12. Immerse slides in dH2O. 13. If desired, counterstain sections with hematoxylin. 14. Wash sections in dH2O two times for 5 min each. 15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each. 16. Mount sections with coverslips and mounting medium.

IHC

Experimental Protocol：

Deparaffinization/Rehydration

1. Deparaffinize/hydrate sections:

2. Incubate sections in three washes of xylene for 5 min each.

3. Incubate sections in two washes of 100% ethanol for 10 min each.

4. Incubate sections in two washes of 95% ethanol for 10 min each.

5. Wash sections two times in dH2O for 5 min each.

6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.

Staining

1. Wash sections in dH2O three times for 5 min each.

2. Incubate sections in 3% hydrogen peroxide for 10 min.

3. Wash sections in dH2O two times for 5 min each.

4. Wash sections in wash buffer for 5 min.

5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.

6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.

7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.

8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.

9. Wash sections three times with wash buffer for 5 min each.

10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.

11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.

12. Immerse slides in dH2O.

13. If desired, counterstain sections with hematoxylin.

14. Wash sections in dH2O two times for 5 min each.

15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.

16. Mount sections with coverslips and mounting medium.

Datasheet & SDS

生物学的記述

Specificity
Melanoma Associated Antigen 100+ / 7 kDa Antibody [G24P23] detects endogenous levels of total Melanoma Associated Antigen 100+ / 7 kDa protein.

タンパク質の局在
小胞体、エンドソーム、ゴルジ装置、細胞内膜系、細胞外環境

Uniprot ID
P40967

Clone
G24P23

Synonym(s)
MAA

Background
Melanoma Associated Antigen 100+ / 7 kDa (MAGE) proteins are tumor-associated antigens, typically restricted to germ cells of the testis in normal adult tissues but aberrantly expressed in various cancers, including melanoma, glioma, lung, bladder, and multiple myeloma. The “100+/7 kDa” designation refers to variants or isoforms with molecular weights around 100 kDa and 7 kDa. Structurally, MAGE proteins share a conserved ~200 amino acid MAGE homology domain (MHD) composed of two winged helix domains forming a deep cleft for peptide or protein binding, flanked by variable N- and C-terminal regions. Functionally, MAGE proteins can act as oncogenic drivers by interacting with RING-type E3 ubiquitin ligases, modulating protein degradation pathways that regulate apoptosis, proliferation, and metabolism; for example, MAGE-A3 promotes tumor survival by stimulating TRIM28-mediated p53 degradation, whereas MAGE-A4 may induce apoptosis via different protein partners. Their tumor-specific expression, structural plasticity, and oncogenic roles make MAGEs both biomarkers and potential therapeutic targets in cancer immunotherapy.

Background

Melanoma Associated Antigen 100+ / 7 kDa (MAGE) proteins are tumor-associated antigens, typically restricted to germ cells of the testis in normal adult tissues but aberrantly expressed in various cancers, including melanoma, glioma, lung, bladder, and multiple myeloma. The “100+/7 kDa” designation refers to variants or isoforms with molecular weights around 100 kDa and 7 kDa. Structurally, MAGE proteins share a conserved ~200 amino acid MAGE homology domain (MHD) composed of two winged helix domains forming a deep cleft for peptide or protein binding, flanked by variable N- and C-terminal regions. Functionally, MAGE proteins can act as oncogenic drivers by interacting with RING-type E3 ubiquitin ligases, modulating protein degradation pathways that regulate apoptosis, proliferation, and metabolism; for example, MAGE-A3 promotes tumor survival by stimulating TRIM28-mediated p53 degradation, whereas MAGE-A4 may induce apoptosis via different protein partners. Their tumor-specific expression, structural plasticity, and oncogenic roles make MAGEs both biomarkers and potential therapeutic targets in cancer immunotherapy.

References
[1] Newman JA, et al. PLoS One. 2016 Feb 24;11(2):e0148762. [2] Guo L, et al. Oncol Lett. 2013 Jul;6(1):55-62.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%